¹ Off-label use in Palliative Care – more common

² than expected. A retrospective chart review

- 3 Vera Hagemann¹
- 4 Claudia Bausewein PhD¹
- 5 Constanze Rémi MSc^{1,2}
- 1 Department of Palliative Medicine, Munich University Hospital, Ludwig-Maximilians-
- 7 University Munich, Germany
- 8 2 Hospital Pharmacy, Munich University Hospital, Ludwig-Maximilians-University
- 9 Munich, Germany
- 10
- 11 Corresponding author:
- 12 Constanze Rémi MSc
- 13 Department of Palliative Medicine and Hospital Pharmacy
- 14 Munich University Hospital
- 15 Marchioninistr. 15
- 16 81377 München, Germany
- 17 Phone: +49(0)89 4400 74962
- 18 Fax: +49(089) 4400 77921
- 19 Email: <u>constanze.remi@med.uni-muenchen.de</u>
- 20 Orcid ID 0000-0001-7655-0306
- 21 Keywords palliative care, off-label use, evidence-based medicine, quality of health
- 22 care, safety
- 23 Word count: 3035
- 24 Reference count: 24

25 **Abstract**

26 **Objective**

Off-label drug use seems to be integral to palliative care pharmacotherapy. Balancing
potential risks and benefits in the context of limited therapeutic options is challenging.
To provide specific support for clinicians in dealing with off-label use, it is essential to
understand off-label use in everyday clinical practice.

The aim of this pilot study was to quantify and describe off-label use in a palliative care unit.

33 Methods

Retrospective chart review of all adult patients treated on a palliative care unit in 10/2017. All data on drug use e.g. indication, dose, route of administration were extracted and matched with the prescribing information. Identified off-label use was subsequently compared with recommendations in the relevant literature. The main outcome measure was frequency and type of off-label drug use.

39 Results

2,352 drug application days (d) and 93 drugs were identified for 28 patients. Of all
drugs, 47 (51%) were used off-label at least once. Most off-label uses concerned
indication (57%), followed by mode of administration. In drugs highly relevant to
palliative care the rate of off-label use was as high as 67%. The extent to which offlabel therapy was supported by literature was very variable and ranged from 0 to
88%.

46 **Conclusions**

This single-unit data confirms the high prevalence of off-label use in palliative
medicine and demonstrates that off-label use in palliative care is very multifaceted.
The data presented allows for a more precise characterization of various aspects of
off-label use in order to derive concrete further measures for research and clinical
practice.

52

What is already known on this subject
 Off-label drug use is likely to be common in palliative care, but detailed data is very limited
 Off-label drug use is a potential threat for patient safety
Physicians state to make therapeutic decisions based on their own experience,
due to a lack of available evidence and lack of support in assessment
What this study adds
off-label use in palliative care is multifaceted
 the mode of administration (e.g. combination with other drugs in a syringe driver) is beside indication a common reasons for off label use the proportion of off-label use without sound evidence is high

67 Introduction

⁶⁸ The aim of palliative care is to improve quality of life of patients with advanced

diseases. Drug therapy is a mainstay in the treatment of physical symptoms.

70 However, based on the few data available so far, it can be assumed that up to a

71 quarter of all prescribed drugs are used outside the scope of the marketing

authorization in palliative care¹⁻⁴. In general, "off-label use" refers to all deviations

from the approval (license) of the drug, for example with regard to indication, route of

⁷⁴ administration, dosage interval or duration of treatment^{5, 6}.

In contrast to other medical disciplines, the management of patients towards the end 75 76 of life does not focus on curative or disease-modifying treatment approaches but on 77 the alleviation of distressing symptoms. Often, only the route of administration or dosage differs from the manufacturer's approval. The existing evidence for off-label 78 79 use in palliative medicine is very heterogeneous, e.g. with good evidence for the use of opioids for breathlessness⁷ but only very limited evidence with case reports and 80 81 small studies on the frequent practice of subcutaneous infusion of midazolam (e.g.⁸, ⁹). 82

Off-label use involves both medical and legal challenges. It always carries the potential risk of a drug that has not been tested or insufficiently tested for its intended use and thus is a potential threat for patient safety¹⁰. Additionally, off-label use can lead to limited coverage of treatment costs by insurance companies or changes in liability for treatment related harm¹¹.

88 Accordingly, it should be applied consciously and well-considered. In clinical practice, 89 however, there is often a lack of time and resources to conduct a patient-specific risk-90 benefit analysis for each therapy on the basis of the current literature and available 91 alternatives¹. Achieving the Hippocratic principle of "Primum non nocere" ("first, do 92 no harm") is therefore often a major challenge. Physicians regularly make therapeutic 93 decisions based on their own experience, especially due to lack of available evidence and lack of support in assessment¹¹. They express concerns about the safety of drug 94 therapy¹¹. To date, there are only limited data to provide a sound evidence-base for 95 96 decision-making on the use of drugs in palliative medicine. In addition, such studies 97 are difficult to conduct due to methodological difficulties. Pharmacists can play an important role in the off-label medication process. Potential tasks include: 98

⁹⁹ identification of off-label therapies, assisting in the interpretation of the available

100 evidence, evaluation of possible treatment alternatives and support in the patient-

101 specific benefit-risk assessment¹².

For providing specific support for clinicians in dealing with off-label use, it is essential to understand off-label use in everyday clinical practice. This includes not only the prevalence but also the clinical circumstances, the underlying evidence and the decision-making processes. Based on this knowledge it is only possible to decide whether measures should be taken to increase safety of therapy and make it possibly more effective for the patient. At the same time, however, such measures can also help to give prescribers more security in dealing with off-label use.

As little is known about off-label use in palliative medicine in Germany and

internationally^{1, 11}, the aim of this pilot study was to quantify and describe off-label

use in adult patients treated on a palliative care unit.

112

113 Methods

114 Medical charts of patients treated in the palliative care unit of the Department of

Palliative Medicine at Munich University Hospital between 1st and 31st October 2017

were retrospectively reviewed. The reporting of this chart review complies with the

117 STROBE criteria for reporting cross-sectional studies¹³.

118

The palliative care unit at Munich University Hospital provides acute palliative care for patients with advanced disease. Annually, about 300 patients are treated in the unit (286 in 2017) of which about 40% are discharged. Patients suffer predominantly from malignant (about 75%) and non-malignant disease.

Prescribing data was extracted for all drugs administered on the unit during October 2017 using an extraction sheet. This month was randomly selected from all months of the year with typical patient case numbers for the unit. The extraction sheet was piloted by two persons and subsequently modified. Data was extracted by two pharmacy students and data integrity randomly checked by two pharmacists. The recording encompassed active generic drug, trade name, indication, dose, dosing

interval, route of administration, mode of administration, and duration of therapy. 129 Drug applications were recorded as application days, i.e. every day on which a drug 130 was administered per patient and not every single dose was counted. This was to 131 132 avoid bias due to short rather than long dosing intervals. The data obtained was 133 compared with the prescribing information to identify off-label applications. An application day was rated as off-label when a drug was applied for an aspect outside 134 135 the scope of the marketing authorisation regarding indication, drug dose, dosing 136 interval, route of administration, mode of administration (e.g. crushed, via feeding 137 tube, combination with other drugs in syringe driver, continuous infusion), and 138 duration of therapy (s. table 1). This was also the case if, for example, morphine was 139 used in an approved indication (pain) but mixed with other substances in the same 140 infusion for administration. Off-label use was subsequently compared with 141 recommendations in the German Guideline on Palliative Medicine for Patients with Incurable Cancer¹⁴ and the German Palliative Care Formulary¹⁵ in order to identify 142 drug uses outside the scope of the marketing authorisation but within the range of 143 144 official or accepted therapy recommendations.

145

Off-label use type	explanation	example
indication	use for an non-labelled indication	morphine for dyspnea
dose	use of a higher or lower dose than licensed	citalopram 40mg/d for a patient >65 years
dosing interval	administration of a drug in a shorter or longer dosing interval than approved	daily change of a fentanyl patch
route of administration	administration via a non licensed route	midazolam subcutaneously
mode of administration	deviations from the approved mode of administration	continuous infusion of levetiracetam
duration of therapy	deviations from the authorized duration of therapy	use of metoclopramide for 10 days
dose titration	a different dose-titration regimen compared to the marketing	increasing the pregabalin dose every other day

authorisation

Tab.1 Off-label use types with explanations and examples from palliative carepractice

148

149 In addition, the following patient data were recorded anonymously: age, disease

150 (malignant/non-malignant) and sex.

151 The evaluation of ambiguous prescriptions was discussed between two pharmacists,

152 for example several or unclear indications of a drug.

153 A committee consisting of two pharmacists and a doctor additionally divided the

identified drugs into three categories based on their relevance in symptom control in

palliative medicine: 1. high relevance, 2. medium relevance, 3. low relevance.

Drugs in the first group (high relevance) included those typically used in symptom

157 control in palliative medicine based on published data and personal experience^{14, 16,}

¹⁷, e.g. opioids, non-opioid analgesics, antiemetics, antipsychotics, benzodiazepines,

antidepressants, antiepileptics, laxatives, anticholinergics and ketamine. Drugs with

160 medium relevance were those used relatively regularly to prevent complications (e.g.

anticoagulants, levothyroxine) but were not prescribed for distressing symptoms. In

addition, drugs with medium relevance were also those used less frequently (e.g.

bisphosphonates, drugs for Parkinson's disease) or for a questionable indication, e.g.

164 proton pump inhibitors and various drugs for insomnia.

165 Drugs considered to be of low relevance were generally those used for comorbidities

166 with no or little impact on current distressing symptoms, e.g. antihypertensives,

167 antidiabetics.

168 Descriptive statistics (frequencies and percentages) were calculated to describe and

summarize all variables using Microsoft excel (version 1902).

170 The Research Ethics Committee of the Ludwig-Maximilians-Universität Munich

171 granted ethical approval for this study (19-445).

172 **Results**

173 The chart review identified a total of 2,352 drug application days (d). Over the period

of one month, 93 different drugs were administered to 28 patients (15 males; 54%)

with a median age of 74 years (range 41-95) on 284 patient days. All but four

patients suffered from malignant disease. Of all drugs, 47 (51%) were used off-label

177 at least once.

178 Of 2,352 application days, 1,248 days (53%) were off-label. Most off-label uses

concerned the indication (56.5%), followed by mode of administration, drug dose,

and route of administration (see Fig.1).

181

182 Figure 1 about here

183

184 The drugs identified were pooled in 19 groups (Tab. 2), according to their

185 pharmacologic group or target symptom. The grouping was decided after discussion

in the research team. It should be noted that some drugs could appear in more than

one group if there was more than one indication or the indication remained unclear,

e.g. melperone and levomepromazine as antipsychotics and hypnotics.

Drug group	Off-label	Application	In-label (d)	Off-label (d)	
	(%)	days			
Anaesthetics ^a	100.0%	17	0	17	
Antipsychotics	89.5%	95	10	85	
Antidepressants	84.3%	153	24	129	
GIT-symptoms ^b	73.1%	186	50	136	
Corticosteroids	71.0%	148	43	105	
Opioids	70.4%	328	97	231	
Benzodiazepine	69.8%	96	29	67	
Hypnotics	65.4%	228	79	149	
Antiemetics	63.1%	195	72	123	
Respiratory tract ^c	46.0%	224	121	103	
Diuretics	45.8%	72	39	33	
Anti-infectives	38.1%	42	26	16	
Other	34.8%	178	116	62	

Non-opioid analgesics	29.8%	188	132	56
Anticoagulation	18.6%	102	83	19
Antiepileptics	17.8%	174	143	31
Laxatives	0%	130	130	0
Cytostatics	0%	13	13	0
Bone metabolism	0%	21	21	0

189 Tab.2 Drug groups used during the study period (descending order of off-label use

- 190 frequency)
- ^aKetamine only drug in group
- ^bDrugs for gastrointestinal symptoms (not antiemetics): esomeprazole, hyoscine butylbromide,
- 193 magaldrat, pantoprazole, saccharomyces boulardii, simeticon
- 194 ^cDrugs for respiratory tract: ambroxol, budesonide, codein, dextromethorphan, formoterol, hyoscine
- 195 butylbromide, ipratropium bromide, salbumatol, tiotropium bromide, tyloxapol
- 196 ^dOther drugs: amlodipine, bisoprolol, epoetin, levodopa/benserazid, levothyroxine, metoprolol,
- 197 naloxone, sage extract, sitagliptin, sodium bicarbonate, sodium polystyrene sulfonate
- 198

199 Prevalence of off-label use in different therapeutic groups

200 The five groups with the most application days were opioids (328 d; 14%), hypnotics (228 d; 10%), respiratory tract (224 d; 10%), antiemetics (195 d; 8%), and non-opioid 201 analgesics (188 d; 8%), see Tab.1. The group with the highest rate of off-label 202 203 applications were anaesthetics, with ketamine as the only group representative. All 204 17 days of use were outside the license, as it was used exclusively in the non-205 approved indication of pain. A likewise large number of uses beyond the license was 206 documented for antipsychotics (95 d; 89%). Of these, 68 application days were related to non-licensed indications (80%). The drug mainly used in this group was 207 quetiapine with 52 application days and an off-label/in-label ratio of 96% (50 d). Of 208 209 these, 33 application days (66%) were for off-label indications like delirium or depression and supported by scientific literature. Haloperidol (9d; 100%) and 210 211 levomepromazine (26d; 100%) were used less frequently, but only outside the 212 approved indication (both used for nausea).

Within the group of opioids, morphine was the drug most commonly used with
152/329 application days (46%). Of the 152 application days, 133 days were off-label
(88%); 101 days (81%) were for the off-label indication dyspnea and supported by

literature recommendations. The remaining 51 applications days (38%) were related
to a non-licensed use in combination with other drugs in the same syringe.

Antidepressants (156 d of all application days; 7%), corticosteroids (148 d of all 218 219 application days; 6%), drugs for anticoagulation (102 d of all application days, 4%), 220 diuretics (72 d of all application days; 3%) and anaesthetics (17d of all application 221 days; 0.7%) differed from all other groups as all uses beyond the license were solely 222 for off-label indications and not for other reasons. In the antidepressant group, 223 mirtazapine (112 d), trimipramine (7 d) and venlafaxin (14 d) summed up to a total of 224 133 days and 97% off-label/in-label-ratio. In the corticosteroid group, all off-label 225 administrations were related to dexamethasone (105 d off-label use; 8% off-label 226 use). Of these five drug groups, diuretics had a relatively low off-label/in-label-ratio 227 (33 d off-label use; 46%), and the off-label days were mainly caused by the use of 228 torasemide (26d) for a differing indication. Dexamethasone and torasemide were 229 both prescribed for edema, dexamethasone additionally for pain. Mirtazapine and 230 trimipramine were used for insomnia, mirtazapine additionally for pain. Venlafaxine was used for pain and aspirin in atrial fibrillation. None of these indications were 231 232 supported by the literature specified above.

In addition to the drug groups, another 20 drugs (22% of all drugs used) were only

used off-label. Twelve drugs were always used in differing indications, s. fig 2 Other

drugs with 100% off-label application days were bisoprolol, levomethadone,

meropenem, simeticone, sitagliptin, budesonide/formoterol, thyme juice, and tilidine.

237 Figure 2 about here

238 Drug relevance in palliative care

The 93 drugs used during the observation period were stratified into groups

according to their relevance for palliative care pharmacotherapy (high, medium, low).

30 (32%) drugs were considered as highly relevant, e.g. ketamine, haloperidol,

242 hyoscine butylbromide, and morphine. The relevance is also reflected by the total

application days of this group. Of 1432/2352 (67%) application days attributable to

drugs in this group, 902 days (63%) were off-label. For 14 of these drugs some

evidence for off-label use could be identified in the literature screened. The type of

off-label use and underlying evidence is displayed in table 3.

2	4	7
_	-	

	Type of off-label use (displayed in applications days)										
	Applic ation days	Off- label use	Indi- cation	Dose	Inter- val	Titra- tion	Du- ration	Mode of Ad- minis- tration	Route	Off-label indication	Under- lying evi-dence
Buprenorphine	4	-	-	-	-	-	-	-	-	-	-
ButyIscopolamin	28	27	21	-	-	-	-	36	-	mostly noisy secretions	German Guideline, APM
Dexamethasone	134	105	105	-	-	-	-	-	8	mostly edema	German Guideline, APM
Dimenhydrinate	12	6	-	-	-	-	-	-	6	-	-
Domperidone	1	-	-	-	-	-	-	-	-	-	-
Fentanyl	33	21	21	-	-	-	-	-	-	dyspnea	German Guideline, APM
Granisetron	21	21	18	-	-	-	-	2	20	nausea/vo miting (not chemother apy associated)	АРМ
Haloperidol	9	9	9	-	-	-	-	-	2	nausea	APM
Hydromorphone	75	49	22	-	-	-	-	25	-	dyspnea	German Guideline, APM
Ketamine	17	17	17	-	-	-	-	8	-	pain	APM
Lacosamide	23	5	-	-	-	5	-	-	-	-	-
Sodiumpico- sulphate	55	-	-	-	-	-	-	-	-	-	-
Levetiracetame	49	20	-	-	-	3	-	12	13	-	-
Levomepromazin	26	26	26	-	-	-	-	4	15	nausea/vo	APM

e										miting	
Levomethadone	1	1	-	-	-	-	-	1	-	-	-
Lorazepam	35	6	-	-	2	-	-	4	-	-	-
Metoclopramide	101	65	-	6	-	-	35	44	4	-	-
Melperone	8	-	-	-	-	-	-	-	-	-	-
Metamizole (dipyrone)	174	48	-	-	-	-	-	96	13	-	-
Midazolam	61	61	61	-	-	-	-	58	22	agitation, anxiety	German Guideline, APM
Mirtazapine	112	108	108	-	-	-	-	-	-	insomnia, pain	APM
Morphine	152	133	101	-	-	-	-	51	-	dyspnea	German Guideline, APM
Movicol	69	-	-	-	-	-	-	-	-	-	-
Ondansetron	2	2	2	-	-	-	-	-	-	nausea/vo miting (not chemother apy associated)	АРМ
Piritramid	59	36	11	18	-	-	-	22	-	dsypnea	German Guideline, APM
Pregabalin	102	6	0	6	-	-	-	-	-	-	-
Quetiapine	52	50	33	17	-	-	-	26	-	delirium, agitation	APM
Tapentadol	1	-	-	-	-	-	-	-	-	-	-
Tilidin	2	2	-	2	-	-	-	-	-	-	-
Venlafaxine	14	14	14	-	-	-	-	-	-	-	-

Table 3. Type of off-label use for drugs highly relevant in palliative care dring the

study period (displayed in application days)

With decreasing relevance of the groups for symptom control, the total number of application days as well as the off-label/in-label ratio dropped: the group of medium relevant drugs (40; 43%; e.g. pantoprazole, enoxaparin) accounted for 714/2352 (30%) of all application days; of these 255/714 (36%) were off-label. The group with the lowest relevance accounted for only 9% (210) of all application days with a total of 83 (40%) off-label application days.

258

259 **Discussion**

Little is known about off-label drug use in palliative care in different national and institutional circumstances. This article provides a first detailed evaluation of off-label use on a palliative care unit in Germany. We aimed to get insights into off-label prescribing and therefore critically evaluated not only the indication but also other areas of off-label use, such as drug dose, dosing interval, route and mode of administration. To our knowledge such an extensive assessment of off-label drug use has not been published for adult palliative care previously.

267 Off-label use was common in this unit with more than half of all drug uses outside the 268 marketing authorisation. Compared to other studies, the frequency of off-label use was rather high in our sample¹. This can partially be explained by the fact that we 269 270 evaluated off-label use not only with regard to indication but to six other aspects of 271 the approval (i.e. dose, mode of application, etc.). The large proportion of off-label 272 use regarding the indications was hardly surprising. Many drugs are not approved for 273 the relatively specific indications in palliative medicine. Still, compared to publications from the UK (14.5%²) and the US (up to 35%¹⁸), the frequency of off-label use was 274 remarkably high. The extent to which the use deviated from the actual approval was 275 276 very heterogeneous. Midazolam, for example, is authorized for sedation in intensive 277 care but not in palliative medicine. In comparison, the established palliative care indication of dyspnea for opioids is not even close to being covered by the approval 278 in Germany, although very well covered by scientific evidence^{19, 20}. In our study, the 279 application mode was the second most common cause for off-label use. The reason 280 281 for this was almost exclusively the non-approved mixing of different substances in a 282 syringe and the subsequent application as continuous infusion. Since data on the 283 compatibility of the mixtures used and on the benefit of a continuous infusion

compared to intermittent injections are only available to a very limited extent, this

285 practice must be critically questioned and discussed in more detail. A route of

administration beyond the approval only came in fourth place in our evaluation.

287 However, when considering subcutaneous administration alone, our assumptions of

288 more common off-label use were confirmed. These findings are consistent with other

studies evaluating subcutaneous adminstration in palliative care (62-85%^{2, 21}).

290 Among drugs and drug groups frequently used off-label were ketamine,

291 antipsychotics, antidepressants, drugs for gastrointestinal symptoms, corticosteroids

and opioids. These were frequently identified in other studies in the context of off-

label use and palliative care aswell^{2, 18, 22}. Based on these findings it seems that

common symptoms in advanced disease like dyspnoea, nausea or vomiting either

295 lack authorized therapies or licensed alternatives are not used. Possible reasons for

the latter, however, cannot be determined due to the retrospective study design.

297 An important finding is the high number of overall off-label application days, the 298 proportion of off-label days in the group of "highly relevant" palliative care drugs, and 299 the decreasing number of overall and off-label application days with decreasing 300 relevance of a drug. This results underpins the high relevance of off-label use in 301 palliative medicine. However, this does not allow for conclusions on the justification 302 of off-label drug use in palliative medicine. Especially the lack of evidence to support off-label use and the high proportion of off-label days without evidence need to be 303 noted. This proportion is rather high compared to other studies (3-11%^{2, 18}). Although 304 we have compared our data with two well-known and established 305 references^{14, 23}, this approach does only allow limited conclusions on the quality of 306

307 the underlying evidence.

308 We assessed off-label use with regard to every aspect of the marketing authorisation,

309 the relevance of drugs for palliative care and the availability of explicit literature

references. Data available so far still only allows limited insights into off-label

311 prescribing behaviour in different institutions and in different national contexts,

though. Reasons that led to a therapeutic decision cannot be illustrated. It is also not

313 clear what role patient-specific or infrastructural factors played in the treatment

selection. To be able to continue working with our and previous findings, it is

important to have the opportunity to compare off-label use in different institutions and

different countries. Such data can serve as a benchmark for quality assurance; they

can help to identify areas that seem to represent therapy standards but with no or
very little available evidence on the other. They can also be used to identify
therapeutic strategies that may be outdated by other approaches. Based on such
comparisons it would also be possible to develop quality indicators for off-label use in
palliative care. Our results demonstrate that there are multiple opportunities for
pharmacists to support off-label use of drugs in clinical routine, especially when
evaluating a treatment or possible treatment alternatives.

324 This study has several limitations. Data extraction was restricted to one month in one 325 palliative care unit. Therefore, data collection on off-label use from different palliative 326 care institutions in Germany is currently being prepared as a follow-up project. 327 Retrospective data collection relies on the quality of the documentation as wrong or 328 missing data cannot be replaced or completed. We were able to extract the required 329 data for all patients that were treated during the period analysed and, in most cases, 330 ambiguities could be resolved based on the patient records. The data presented here 331 is from 2017 and might be considered outdated. However, for a retrospective 332 evaluation of prescribing data, a time delay until the data is available should always be expected. Furthermore an update and extension of the German Guideline on 333 Palliative Medicine for Patients with Incurable Cancer²⁴ has been published and its 334 335 influence on prescribing behaviour is not clear. It will therefore be interesting to 336 compare whether it had an impact on off-label prescribing behaviour.

337 Off label use is an integral part of palliative medicine. With very strict consideration, 338 which does not only focus on the indication, the extent may be even greater than 339 previously known. Off-label use should not be a routine but rather encourage to 340 question a therapy. At the same time, however, it must be possible to prescribe well-341 established and scientifically sound therapies without justification if appropriate for an 342 individual patient. Ultimately, it is important to critically question the necessity of 343 every drug - whether inside or outside the marketing authorisation, for every patient. 344 As an important first step, the data presented here allow for a more precise 345 characterization of various aspects of off-label use in everyday clinical practice in 346 order to use this knowledge to derive concrete further measures for research and 347 clinical practice. As a follow-up to this pilot study, the next step will be to collect and evaluate data on off-label use in various palliative care settings. These results will 348 349 then be used, in part, for quality assurance in the off-label drug use in palliative care.

350

351 **Conflict of interest statement**

- 352 The Authors declare that there are no competing interests. This project did not
- 353 receive funding.

354

355 Acknowledgements

The authors would like to thank Stefanie Büsel for assisting in the data extraction process.

References

 Hagemann V, Bausewein C, Remi C. Drug use beyond the licence in palliative care: A systematic review and narrative synthesis. *Palliative Medicine*.
 2019:33(6):650-62.

2. Atkinson C, Kirkham S. Unlicensed uses for medication in a palliative care unit. *Palliative Medicine*. 1999;13:145–52.

3. Todd J, Davies A. Use of unlicensed medication in palliative medicine. *Palliative Medicine*. 1999;13:466.

4. García-López I, Cuervas-Mons Vendrell M, Martín Romero I, de Noriega I, Benedí González J, Martino-Alba R. Off-Label and Unlicensed Drugs in Pediatric Palliative Care: A Prospective Observational Study. *Journal of pain and symptom management*. 2020.

5. FDA. Understanding Unapproved Use of Approved Drugs "Off Label" [cited 2019 Feb 05]. 2018 [updated 02/05/201808/02/2019]. Available from: https://www.fda.gov/forpatients/other/offlabel/default.htm.

 Aronson JK, Ferner RE. Unlicensed and off-label uses of medicines: definitions and clarification of terminology. *Br J Clin Pharmacol.* 2017;83(12):2615-25.

7. Johnson MJ, Currow DC. Opioids for breathlessness: a narrative review. *BMJ* supportive & palliative care. 2020;10(3):287-95.

8. Gremaud G, Zulian GB. Indications and Limitations of Intravenous and Subcutaneous Midazolam in a Palliative Care Center. *Journal of pain and symptom management*. 1998;15(6):331-3.

9. Amesbury BDW, Dunphy KP. The use of subcutaneous midazolam in the home care setting. *Palliative Medicine*. 1989;3:299–301.

10. Eguale T, Buckeridge DL, Verma A, Winslade NE, Benedetti A, Hanley JA, et al. Association of Off-label Drug Use and Adverse Drug Events in an Adult Population. *JAMA internal medicine*. 2016;176(1):55-63.

 Hagemann V, Bausewein C, Rémi C. Off-label-prescriptions in daily clinical practice – a cross-sectional national survey of palliative medicine physicians.
 Progress in Palliative Care. 2019:1-6.

12. Nationale Akademie der Wissenschaften Leopoldina und Union der deutschen Akademien der Wissenschaften. Palliativversorgung in Deutschland – Perspektiven

für Praxis und Forschung. 2015. Available from:

http://www.leopoldina.org/uploads/tx_leopublication/2015_Palliativversorgung_LF_D E.pdf.

13. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. *International journal of surgery (London, England)*. 2014;12(12):1495-9.

14. Leitlinienprogramm Onkologie. S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Tumorerkrankung 2015 [Available from:

http://leitlinienprogramm-

onkologie.de/uploads/tx sbdownloader/LL Palliativmedizin Langversion 1 1.pdf.

15. Rémi C, Bausewein C, Twycross R, Wilcock A, Howard P, editors.

Arzneimitteltherapie in der Palliativmedizin. 2 ed. München: Urban & Fischer; 2015.

16. Essential medicine in palliative care: executive summary [Internet]. 2013 [cited14.08.2015]. Available from:

http://www.who.int/selection_medicines/committees/expert/19/applications/PalliativeC are_8_A_R.pdf.

17. Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, et al. Drugs in palliative care: results from a representative survey in Germany. *Palliative Medicine*. 2004;18:100-7.

18. Kwon JH, Kim MJ, Bruera S, Park M, Bruera E, Hui D. Off-label Medication Use in the Inpatient Palliative Care Unit. *J Pain Symptom Manage*. 2017.

19. Ekstrom M, Bajwah S, Bland JM, Currow DC, Hussain J, Johnson MJ. One evidence base; three stories: do opioids relieve chronic breathlessness? *Thorax*. 2017;73(1):88-90.

20. Barnes H, McDonald J, Smallwood N, Manser R. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. *Cochrane Database Syst Rev.* 2016;3:Cd011008.

21. Toscani F, Di Giulio P, Campi R, Pellerin I, De Luca A, Casale G. Off-label prescriptions in Italian hospices: a national survey. *J Pain Symptom Manage*. 2009;38(3):365-71.

22. Culshaw J, Kendall D, Wilcock A. Off-label prescribing in palliative care: a survey of independent prescribers. *Palliative Medicine*. 2013;27(4):314-9.

23. Rémi C, Bausewein C, Twycross R, Wilcock A, Howard P, editors.Arzneimitteltherapie in der Palliativmedizin. 3 ed. München: Elsevier Urban & Fischer; 2018.

24. Leitlinienprogramm Onkologie. Erweiterte S3-Leitlinie Palliativmedizin für Patienten mit einer nicht-heilbaren Krebserkrankung. Langversion 2.0–August 2019 AWMF-Registernummer: 128/001-OL 2019 [Available from:

https://www.leitlinienprogramm-

onkologie.de/fileadmin/user_upload/Downloads/Leitlinien/Palliativmedizin/Version_2/ LL_Palliativmedizin_2.0_Langversion.pdf.



Fig. 1 Frequency of off-label application days by type of off-label use

total number of drug applications days (in-label and off-label): 2,352

*off-label uses could occur in more than one category resulting in a higher total number of off-label uses than application days.



